Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-29T04:11:26.833Z Has data issue: false hasContentIssue false
  • English
  • Français

Carbamazepine and NMS

Published online by Cambridge University Press:  02 January 2018

Fiona Coulter  and
F. M. Corrigan
Fiona Coulter
Affiliation:
Department of Psychological Medicine, Gartnavel General Hospital, Glasgow G12 0YN
F. M. Corrigan
Affiliation:
Argyll and Bute Hospital, Lochgilphead, Argyll
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
The British Journal of Psychiatry , Volume 158 , Issue 3 , March 1991 , pp. 434 - 435
Copyright
Copyright © Royal College of Psychiatrists, 1991 

References

Corrigan, F. M. & Coulter, F. (1987) Neuroleptic malignant syndrome. Amitriptyline and thioridazine. Biological Psychiatry, 23, 320–321.Google Scholar
Elphick, M. Yang, J. D. & Cowen, P. J. (1990) Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses. Archives of General Psychiatry, 47, 135–140.Google Scholar
Halman, M. & Goldbloom, D. S. (1990) Fluoxetine and neuroleptic malignant syndrome. Biological Psychiatry, 28, 518–521.Google Scholar
Marangos, P. J. Post, R. M. Patel, J. et al (1983) Specific and potent interactions of carbamazepine with brain adenosine receptors. European Journal of Pharmacology, 93, 175–182.Google Scholar
Toru, M. Matsuda, O. Makiguchi, K. et al (1981) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. Journal of Nervous and Mental Disease, 169, 324–327.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.